Clinical Trial Detail

NCT ID NCT01971489
Title PI3K Inhibitor BKM120, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements No
Sponsors Roswell Park Cancer Institute
Indications

Advanced Solid Tumor

Therapies

Buparlisib + Cisplatin + Gemcitabine

Age Groups: adult senior

No variant requirements are available.